STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

Ilaria Attili, Niki Karachaliou, Laura Bonanno, Jordi Berenguer, Jillian Bracht, Jordi Codony-Servat, Carles Codony-Servat, Masaoki Ito, Rafael Rosell

Research output: Contribution to journalArticle

Abstract

Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

Original languageEnglish
Pages (from-to)1758835918763744
JournalTherapeutic Advances in Medical Oncology
Volume10
DOIs
Publication statusPublished - 2018

Fingerprint

Oncogenes
Non-Small Cell Lung Carcinoma
Immunotherapy
Biomarkers
Cellular Microenvironment
Tumor Microenvironment
Lung Neoplasms
Neoplasms
Therapeutics

Cite this

Attili, I., Karachaliou, N., Bonanno, L., Berenguer, J., Bracht, J., Codony-Servat, J., ... Rosell, R. (2018). STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 10, 1758835918763744. https://doi.org/10.1177/1758835918763744

STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. / Attili, Ilaria; Karachaliou, Niki; Bonanno, Laura; Berenguer, Jordi; Bracht, Jillian; Codony-Servat, Jordi; Codony-Servat, Carles; Ito, Masaoki; Rosell, Rafael.

In: Therapeutic Advances in Medical Oncology, Vol. 10, 2018, p. 1758835918763744.

Research output: Contribution to journalArticle

Attili, I, Karachaliou, N, Bonanno, L, Berenguer, J, Bracht, J, Codony-Servat, J, Codony-Servat, C, Ito, M & Rosell, R 2018, 'STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer', Therapeutic Advances in Medical Oncology, vol. 10, pp. 1758835918763744. https://doi.org/10.1177/1758835918763744
Attili, Ilaria ; Karachaliou, Niki ; Bonanno, Laura ; Berenguer, Jordi ; Bracht, Jillian ; Codony-Servat, Jordi ; Codony-Servat, Carles ; Ito, Masaoki ; Rosell, Rafael. / STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. In: Therapeutic Advances in Medical Oncology. 2018 ; Vol. 10. pp. 1758835918763744.
@article{84f5b1194fe041fc954d2379402eb792,
title = "STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer",
abstract = "Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.",
author = "Ilaria Attili and Niki Karachaliou and Laura Bonanno and Jordi Berenguer and Jillian Bracht and Jordi Codony-Servat and Carles Codony-Servat and Masaoki Ito and Rafael Rosell",
year = "2018",
doi = "10.1177/1758835918763744",
language = "English",
volume = "10",
pages = "1758835918763744",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer

AU - Attili, Ilaria

AU - Karachaliou, Niki

AU - Bonanno, Laura

AU - Berenguer, Jordi

AU - Bracht, Jillian

AU - Codony-Servat, Jordi

AU - Codony-Servat, Carles

AU - Ito, Masaoki

AU - Rosell, Rafael

PY - 2018

Y1 - 2018

N2 - Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

AB - Immune checkpoint blockade has modified the treatment landscape for many types of tumors, including lung cancer. Still our knowledge on the biology of the interaction between tumor cells and the microenvironment is limited, preventing the optimal use of these new compounds and the maximum benefit that the patients can derive from them. We have actively worked on the role of STAT3, a transcriptional factor that causes innate resistance to targeted therapies in oncogene-addicted tumors. In this short review we take the opportunity to express our opinion and review existing knowledge on the immune role of STAT3 and the possible implications that this may have for the discovery of new biomarkers to predict response to immunotherapy, as well as new partners to combine with and increase the efficacy of immune checkpoint inhibitors.

U2 - 10.1177/1758835918763744

DO - 10.1177/1758835918763744

M3 - Article

C2 - 29636826

VL - 10

SP - 1758835918763744

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

ER -